ABBV - AbbVie Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
92.73
-1.59 (-1.69%)
As of 1:48PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close93.59
Open94.43
Bid92.50 x 100
Ask92.53 x 300
Day's Range91.40 - 94.52
52 Week Range63.29 - 125.86
Volume2,741,321
Avg. Volume7,709,122
Market Cap147.134B
Beta1.64
PE Ratio (TTM)28.10
EPS (TTM)3.30
Earnings DateApr 26, 2018
Forward Dividend & Yield3.84 (4.18%)
Ex-Dividend Date2018-04-12
1y Target Est121.38
Trade prices are not sourced from all markets
  • Gilead Sciences Expects Decline in Earnings in Fiscal 2018
    Market Realist6 hours ago

    Gilead Sciences Expects Decline in Earnings in Fiscal 2018

    Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.

  • Moody's9 hours ago

    Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising

    The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.

  • Roche Hemophilia Drug Gets Breakthrough Therapy Designation
    Zacks19 hours ago

    Roche Hemophilia Drug Gets Breakthrough Therapy Designation

    The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.

  • Gilead Sciences May Witness Significant Drop in Revenues in 2018
    Market Realist20 hours ago

    Gilead Sciences May Witness Significant Drop in Revenues in 2018

    Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...

  • What Analysts Recommend for Gilead Sciences in April 2018
    Market Realist22 hours ago

    What Analysts Recommend for Gilead Sciences in April 2018

    In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.

  • Analysts’ Recommendations for AbbVie in April 2018
    Market Realistyesterday

    Analysts’ Recommendations for AbbVie in April 2018

    In April 2018, the FDA notified AbbVie (ABBV) and Neurocrine Biosciences that it would need more time to review liver function test data provided by AbbVie with its new drug application for Elagolix for the management of endometriosis-associated pain, extending its Prescription Drug User Fee Act goal date by three months to 3Q18. In 4Q17, the FDA granted Elagolix priority review. In clinical trials, Elagolix was evaluated for safety and efficacy in ~1,700 women with moderate-to-severe endometriosis-related pain.

  • PR Newswireyesterday

    AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference

    NORTH CHICAGO, Ill. , April 18, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Deutsche Bank's 43 rd Annual Health Care Conference ...

  • AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane
    Market Realistyesterday

    AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane

    In 4Q17, AbbVie’s (ABBV) Duodopa generated revenue of $100 million, marking ~28% growth YoY (year-over-year) and 6% growth quarter-over-quarter. In US and international markets, Duodopa saw revenue of $17 million and $77 million, respectively, reflecting ~55.2% and ~23% growth YoY.

  • The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox
    Zacksyesterday

    The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox

    The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox

  • Top Analyst Reports for AbbVie, Berkshire & PepsiCo
    Zacks2 days ago

    Top Analyst Reports for AbbVie, Berkshire & PepsiCo

    Top Analyst Reports for AbbVie, Berkshire & PepsiCo

  • Investopedia2 days ago

    7 Stock Picks With Giant Upside: Goldman

    Green Pastures: DISH, AbbVie, Hasbro and other stocks are poised to flourish

  • 5 Drug Stocks Poised to Surpass on Earnings This Quarter
    Zacks2 days ago

    5 Drug Stocks Poised to Surpass on Earnings This Quarter

    The outlook for the upcoming first-quarter results looks bright.

  • Novartis’s 1Q18: Analysts Expect Revenue Growth
    Market Realist2 days ago

    Novartis’s 1Q18: Analysts Expect Revenue Growth

    Analysts expect Novartis’s (NVS) revenue to rise ~8.8% to $12.6 billion in 1Q18 following growth in operating revenues across all three of its segments during the quarter.

  • Updates on AbbVie’s AndroGel, Lupron, and Kaletra
    Market Realist2 days ago

    Updates on AbbVie’s AndroGel, Lupron, and Kaletra

    In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter. In fiscal 2017, AndroGel generated revenue of $577 million, marking a ~14.5% decline YoY.

  • Risankizumab Could Be AbbVie’s Long-Term Growth Driver
    Market Realist2 days ago

    Risankizumab Could Be AbbVie’s Long-Term Growth Driver

    In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.

  • AbbVie’s Imbruvica in 4Q17 and Fiscal 2017
    Market Realist2 days ago

    AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

    AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.

  • How AbbVie’s Humira Performed in 4Q17 and 2017
    Market Realist3 days ago

    How AbbVie’s Humira Performed in 4Q17 and 2017

    AbbVie’s (ABBV) Humira generated revenue of $4.9 billion in 4Q17 and $4.3 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~4% growth quarter-over-quarter. In 4Q17, in US and international markets, Humira reported revenue of $3.3 billion and $1.6 billion, respectively, marking ~15.1% and ~11.7% growth YoY.

  • Upadacitinib Could Drive AbbVie’s Long-Term Growth
    Market Realist3 days ago

    Upadacitinib Could Drive AbbVie’s Long-Term Growth

    In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis. The trial met its primary endpoint of improved ACR201 scores and clinical remission.

  • GlobeNewswire3 days ago

    Consolidated Research: 2018 Summary Expectations for Amazon, Rayonier, The Boeing, Sanchez Energy, AbbVie, and American Airlines Group — Fundamental Analysis, Key Performance Indications

    NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Johnson & Johnson’s Revenue Estimates for 1Q18
    Market Realist3 days ago

    Johnson & Johnson’s Revenue Estimates for 1Q18

    As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.

  • Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
    Zacks6 days ago

    Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III

    Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.

  • Exploring Voyager Therapeutics’ Research Pipeline
    Market Realist6 days ago

    Exploring Voyager Therapeutics’ Research Pipeline

    Voyager Therapeutics’ (VYGR) research pipeline consists of six programs targeting different neurological indications, including advanced Parkinson’s disease, amyotrophic lateral sclerosis (or ALS), Huntington’s disease, and Alzheimer’s disease. Voyager Therapeutics’ most advanced clinical candidate is VY-AADC for the treatment of advanced Parkinson’s disease.

  • Better Buy: AbbVie Inc. vs. Eli Lilly
    Motley Fool6 days ago

    Better Buy: AbbVie Inc. vs. Eli Lilly

    How the giant drugmakers compare when it comes to growth, dividends, and valuation.

  • Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar
    Zacks7 days ago

    Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar

    Mylan (MYL) is partnering with Fujifilm Kyowa to commercialize a biosimilar to Humira (adalimumab).

  • Investopedia7 days ago

    AbbVie Stock Is Signaling That a Move to the Upside Could Be Near

    A recent pullback, dividend growth and institutional accumulation could make AbbVie shares an attractive long-term investment.